B. H. Moreno

发表

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

J. Sosman, A. Ribas, Douglas B. Johnson, 2016, Cell.

Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065))

J. Sosman, A. Ribas, Douglas B. Johnson, 2017 .

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Robert Damoiseaux, Antoni Ribas, Begonya Comin-Anduix, 2017, Cell reports.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

T. Graeber, A. Ribas, R. Damoiseaux, 2019, Cell reports.

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

G. Gibney, M. Brown, N. Ibrahim, 2021, Clinical Cancer Research.

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules

D. Baltimore, A. Ribas, O. Witte, 2018, Proceedings of the National Academy of Sciences.

3 in a Murine Melanoma Syngeneic Model Requires 4 Costimulation, CD4, and CD8 T Cells

T. Graeber, A. Weeraratna, A. Ribas, 2016 .

2 Response to Programmed Q 1 Cell Death-1 Blockade Q 2 3 in a Murine Melanoma Syngeneic Model Requires 4 Costimulation , CD 4 , and CD 8 T Cells 5

T. Graeber, A. Weeraratna, A. Ribas, 2016 .

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

J. Wolchok, A. Ribas, F. Hodi, 2021, European journal of cancer.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

T. Powles, A. Alva, S. Oudard, 2020 .

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

M. Milowsky, S. Srinivas, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

J. Sosman, A. Ribas, Douglas B. Johnson, 2017, Cell.

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.

T. Choueiri, M. Atkins, A. Ribas, 2017 .

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

A. Ribas, A. Coxon, R. Kendall, 2017, Oncotarget.

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

T. Powles, E. Plimack, D. Bajorin, 2021 .

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma

R. Fisher, A. Ribas, F. Hodi, 2017 .

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

T. Powles, E. Plimack, A. Balar, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

M. Milowsky, P. O’Donnell, D. Petrylak, 2022, Annals of Oncology.

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

M. Galsky, H. Nishiyama, J. Bedke, 2021 .

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

E. Plimack, J. Witjes, M. Galsky, 2021 .

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Abstract 2682: Melanoma phenotype switching to adapt to BRAF inhibition

T. Graeber, A. Ribas, L. Robert, 2015 .

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Network Boston.

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

A. Ribas, B. H. Moreno, B. Homet Moreno, 2015, British Journal of Cancer.

1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.

T. Powles, A. Alva, S. Oudard, 2021 .

747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052

J. Lunceford, T. Powles, M. Climent, 2020 .

Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.

H. Nishiyama, G. Steinberg, A. Siefker-Radtke, 2020 .

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.

A. Balar, R. de Wit, P. Grivas, 2023, European urology.

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma.

P. Ascierto, N. Ibrahim, A. Ribas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.